Title : Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.

Pub. Date : 2020 May

PMID : 32642151






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial. Docetaxel epidermal growth factor receptor Homo sapiens
2 Conclusions: Apatinib plus docetaxel is an effective and tolerable treatment option for advanced non-squamous NSCLC with wild-type EGFR. Docetaxel epidermal growth factor receptor Homo sapiens